Ventyx Biosciences

Ventyx Biosciences company information, Employees & Contact Information

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our deep expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drugs through clinical trials. Our lead portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor, and VTX3232, a CNS-penetrant NLRP3 inhibitor. Our inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator and VTX958, a TYK2 inhibitor, both of which have completed Phase 2 clinical trials.

Company Details

Employees
268
Address
12790 El Camino Real, San Diego,california,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Diego, California
Looking for a particular Ventyx Biosciences employee's phone or email?

Ventyx Biosciences Questions

News

Ventyx Biosciences Announces Positive Topline Results from - GlobeNewswire

Ventyx Biosciences Announces Positive Topline Results from GlobeNewswire

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference - Yahoo Finance

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference Yahoo Finance

Clinical-Stage Biotech Ventyx Biosciences Lines Up Three Major Healthcare Conference Presentations in September - Stock Titan

Clinical-Stage Biotech Ventyx Biosciences Lines Up Three Major Healthcare Conference Presentations in September Stock Titan

Ventyx Bio Cardiovascular Drug’s Phase 2 Results Set Up Talks With a Big Pharma Firm - MedCity News

Ventyx Bio Cardiovascular Drug’s Phase 2 Results Set Up Talks With a Big Pharma Firm MedCity News

Ventyx Biosciences Reports Positive Phase 2a Study Results for VTX3232 in Early-Stage Parkinson's Disease - Nasdaq

Ventyx Biosciences Reports Positive Phase 2a Study Results for VTX3232 in Early-Stage Parkinson's Disease Nasdaq

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress - Yahoo Finance

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress Yahoo Finance

Ventyx (NASDAQ: VTYX) Phase 2: IL-6 ≤1.65 ng/L; combo boosts Lp(a) and liver markers - Stock Titan

Ventyx (NASDAQ: VTYX) Phase 2: IL-6 ≤1.65 ng/L; combo boosts Lp(a) and liver markers Stock Titan

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress - Yahoo Finance

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress Yahoo Finance

Breakthrough: New Oral Drug Shows Powerful Results in Early-Stage Parkinson's Disease Trial - Stock Titan

Breakthrough: New Oral Drug Shows Powerful Results in Early-Stage Parkinson's Disease Trial Stock Titan

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress - GlobeNewswire

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress GlobeNewswire

Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis - Yahoo Finance

Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis Yahoo Finance

Ventyx Biosciences Announces Presentation of Data from the - GlobeNewswire

Ventyx Biosciences Announces Presentation of Data from the GlobeNewswire

Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi - GlobeNewswire

Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi GlobeNewswire

Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress - GlobeNewswire

Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress GlobeNewswire

Ventyx Biosciences Presents New 52-Week Results from the - GlobeNewswire

Ventyx Biosciences Presents New 52-Week Results from the GlobeNewswire

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio - GlobeNewswire

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio GlobeNewswire

Ventyx Biosciences Reports Clinical Data for its NLRP3 - GlobeNewswire

Ventyx Biosciences Reports Clinical Data for its NLRP3 GlobeNewswire

Ventyx Biosciences Raises $114 Million Financing led by venBio Partners to Advance Diverse Pipeline of Immunology Programs - PR Newswire

Ventyx Biosciences Raises $114 Million Financing led by venBio Partners to Advance Diverse Pipeline of Immunology Programs PR Newswire

Top Ventyx Biosciences Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant